Ovarian Cancer Immature Teratoma Type in Pregnancy: Management and Feto-Maternal Outcomes

Lany Christina Prajawati Ni Luh; Bayu Mahendra I Nyoman; Putra Wiradnyana AAG; Ariawati Ketut; Sri Mahendra Dewi I Gusti Ayu

doi:10.3889/oamjms.2019.129

Authors

Lany Christina Prajawati Ni Luh Department of Obstetrics and Gynaecology, Pediatrics, Anatomical Pathology, Medical Science Faculty of Udayana University, Sanglah Hospital, Bali, Indonesia
Bayu Mahendra I Nyoman Department of Obstetrics and Gynaecology, Pediatrics, Anatomical Pathology, Medical Science Faculty of Udayana University, Sanglah Hospital, Bali, Indonesia
Putra Wiradnyana AAG Department of Obstetrics and Gynaecology, Pediatrics, Anatomical Pathology, Medical Science Faculty of Udayana University, Sanglah Hospital, Bali, Indonesia
Ariawati Ketut Department of Obstetrics and Gynaecology, Pediatrics, Anatomical Pathology, Medical Science Faculty of Udayana University, Sanglah Hospital, Bali, Indonesia
Sri Mahendra Dewi I Gusti Ayu Department of Obstetrics and Gynaecology, Pediatrics, Anatomical Pathology, Medical Science Faculty of Udayana University, Sanglah Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.129

Keywords:

Pregnancy, BEP chemotherapy, Premature ovarian failure (POF), Surgical staging, Immature teratoma

Abstract

BACKGROUND: Immature teratoma is malignant ovarian germ cell tumours (MOGCTs). The case in pregnancy is very rare which less than 1% of all ovarian teratoma cases. The aim is to reach optimal and comprehensive management for immature ovarian teratoma in pregnancy to gain the healthiest maternal and fetal outcomes.

CASE PRESENTATION: Thirty-one years old female G2P1A0, 8 weeks 1-day pregnancy, with left ovarian solid tumour 15 x 15 x 15 cm in size. At gestational age (GA) of 19 weeks 5 days, the size of the tumour was increasing rapidly to 30 x 30 x 30 cm. Alfa-fetoprotein raised to 699.9 IU/mL and LDH 579 U/L. The patient had gone primary conservative left oophorectomy, omentectomy, and ascites fluid cytology with histopathological conclusion grade II immature teratoma of left ovary containing the immature neuroepithelial and fat component: magnetic resonance imaging (MRI) at 25 weeks 3 days GA, no spreading. Amniocentesis performed at 27 weeks 2 days GA, the fetus had normal 46 chromosomes and sex XX without major structural abnormality. The patient had BEP chemotherapy start at 27 weeks 2 days GA. Patient in labour at 40 weeks 2 days GA. The female baby had spontaneous delivery with 2700 grams in body weight without congenital abnormality. Complete surgical staging performed at 58th days postpartum and histopathological result there was no malignant cell anymore, but post-chemotherapy ovarian atrophy feature had found on the contralateral ovary. The patient showed psychosocial problem including post-chemotherapy depression and premature ovarian failure (POF). Immunohistochemistry (IHC) ER and PR of teratoma tissue showed immature component had ER (-) and PR (+). Follow up of the baby was in good condition.

CONCLUSION: BEP chemotherapy become regimen choice for this case with fetal outcomes was good, but there was a POF sign on the mother. Survival of patient on this case is 62%, free recurrence survival post-BEP 84% and progressivity post complete surgical staging 8% without delay the chemotherapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Health Department Republic of Indonesia. Pusat Data dan Informasi 2015, 2015.

Berek JS, Friedlander ML, Hacker NF. Germ Cell and Nonepithelial Ovarian Cancer In: Berek and Hacker's Gynecologic Oncology. 6th Edition. Philladelphia: Wolters Kluwer, 2015: 539-41.

Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surgical oncology. 2011; 20(4):e175-85. https://doi.org/10.1016/j.suronc.2011.06.002 PMid:21733678

Robert JK, Lora HE, Brigitte MR. Blaustein's Pathology of the Female Genital Tract. Sixth Edition. New York: Springer, 2011.

Amant F, et al. Gynaecologic Cancer Complicating Pregnancy: An Overview. Best Practice&Research Clinical Obstetrics and Gynaecology. 2010; 24:61-79. https://doi.org/10.1016/j.bpobgyn.2009.08.001 PMid:19740709

Ali MK, Abdelbadee AY, Shazly SA, Abbas AM. Adnexal torsion in the first trimester of pregnancy: A case report. Middle East Fertility Society Journal. 2013; 18(4):284-6. https://doi.org/10.1016/j.mefs.2012.05.002

de Haan J, Verheecke M, Amant F. Management of ovarian cysts and cancer in pregnancy. Facts, views & vision in Ob Gyn. 2015; 7(1):25-31. PMid:25897369 PMCid:PMC4402440

Jeon SY, Hwang KA, Choi KC. Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development. The Journal of steroid biochemistry and molecular biology. 2016; 16: 1-32. https://doi.org/10.1016/j.jsbmb.2016.02.005 PMid:26873134

Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V. Cancer chemotherapy and pregnancy. SOGC Clinical Practice Guideline. 2013; 288:263-78. https://doi.org/10.1016/S1701-2163(15)30999-3

Shaaban AM, Rezvani M, Elsayes KM, Baskin Jr H, Mourad A, Foster BR, Jarboe EA, Menias CO. Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics. 2014; 34:778. https://doi.org/10.1148/rg.343130067 PMid:24819795

Budiana ING. Tumor Ovarium: Prediksi Keganasan Prabedah. Jurnal Ilmiah Kedokteran. 2013; 44:179-85.

Jain M, Budhwani C, Jain AK, Hazari RA. Pregnancy with ovarian dysgerminoma: an unusual diagnosis. Journal of Dental and Medical Sciences. 2013; 11(5):53-7. https://doi.org/10.9790/0853-1155357

Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet. 2012; 379(9815):558-69. https://doi.org/10.1016/S0140-6736(11)60829-5

Ngu S, Cheung VY, Pun T. 2014. Surgical Management of Adnexal Masses in Pregnancy. Journal of the Society of Laparoendoscopic Surgeons. 2014; 18:71-5. https://doi.org/10.4293/108680813X13693422521007

Morgan S. How Do Chemotherapeutic Agents Damage the Ovary? Edinburgh: The University of Edinburgh, 2014.

Gui T, Cao D, Shen K, Yang J, Fu C, Lang J, Liu X. Management and Outcome Ovarian, 2013.

Gezginc K, Karatayli R, Yazici F, Acar A, Celik C, Capar M. Ovarian Cancer during Pregnancy. International Journal of Gynecology and Obstetrics. 2011; 115:150-3. https://doi.org/10.1016/j.ijgo.2011.05.025 PMid:21872237

Kodama M, Grubbs BH, Blake EA, Cahoon SS, Murakami R, Kimura T, Matsuo K. Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014; 181:145-56. https://doi.org/10.1016/j.ejogrb.2014.07.047 PMid:25150953

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics. 2012; 67(5):437-41. https://doi.org/10.6061/clinics/2012(05)06

Stavrou S, Domali E, Paraoulakis I, Haidopoulos D, Thomakos N, Loutradis D, Drakakis P. Immature Ovarian Terratoma in 21 Year-Old Woman. A Case Report and Review of the Literature. J Gen Pract. 2016; 4(2):1-4.

Shahzadi SH. Immature Placental Teratoma. Case Report. J Postgrad Med Inst. 2014; 28(3):324-7.